Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1415762
This article is part of the Research Topic Multidisciplinary and Personalized Approach in the Treatment of Advanced Breast Cancer View all 8 articles

Clinicopathologic Significance of Heat Shock Protein 60 as a Survival Predictor in Breast Carcinoma

Provisionally accepted
Qing Wang Qing Wang *Shengzhou Chen Shengzhou Chen Zhihong Wu Zhihong Wu Jungang Ni Jungang Ni
  • Department of Thyroid and Breast Surgery, Yiwu Central Hospital, Yiwu, China

The final, formatted version of the article will be published soon.

    Background: While Heat Shock Protein 60 (HSP60) has been linked to human tumour, its clinic significance specifically in breast carcinoma is unclear. This investigation aims to retrospectively evaluate how HSP60 protein levels relate to survival outcomes among patients diagnosed with breast carcinoma. Methods: Evaluation of 206 patients diagnosed with breast carcinoma and receiving treatment from January 2012 to April 2018, carried out retrospectively. The protein level of HSP60 in breast carcinoma determined by immunohistochemical. Results: The study provided evidence of a distinct upregulation of HSP60 expression in breast carcinoma tumour samples in contrast to adjacent normal tissue samples. Additionally, heightened HSP60 expression was linked to advanced T stage (P = 0.046), N stage (P = 0.034), tumour metastasis (P = 0.016), pathological grading (P = 0.012), and adjuvant therapy utilization (P = 0.004). Moreover, elevated levels of HSP60 proteins exhibited a significant inverse correlation with overall survival (OS) [hazard ratio (HR) 1.598, P = 0.018] and progression-free survival (PFS) (HR 1.600, P = 0.017) among breast carcinoma patients in univariate analyses. The results of multivariate analyses highlighted HSP60 may serve as an independent predictor for both OS and PFS in breast carcinoma patients (HR 1.525, P = 0.034; HR 1.528, P = 0.033, respectively). Conclusion: The involvement of HSP60 in breast carcinoma progression suggests its potential clinical relevance in treatment target validation and prognostic assessment of the disease.

    Keywords: HSP60, prognosis, overall survival, Progression-free survival, breast carcinoma

    Received: 11 Apr 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Wang, Chen, Wu and Ni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qing Wang, Department of Thyroid and Breast Surgery, Yiwu Central Hospital, Yiwu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.